Rapamycin and tacrolimus differentially modulate acute graft-versus-host disease in rats after liver transplantation

Liver Transplantation

Volumn 16, Issue 3, 2010, Pages 357-363

  Xu, Guodong ^a   Wang, Linyan ^a   Chen, Wei ^a   Xue, Fei ^c   Bai, Xueli ^a   Liang, Liang ^a   Shen, Xuning ^a   Zhang, Mangli ^a   Xia, Dajing ^b   Liang, Tingbo ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HOMEOSTASIS AND REGULATION; IMMUNOHISTOCHEMISTRY; INTESTINE CELL; LIVER TRANSPLANTATION; MALE; MORTALITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; SURVIVAL TIME;

ANIMALS; ANTIGENS, CD4; BIOPSY; DISEASE MODELS, ANIMAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT VS HOST DISEASE; HOMEOSTASIS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIVER TRANSPLANTATION; MALE; RATS; RATS, INBRED LEW; SIROLIMUS; SKIN; T-LYMPHOCYTES, REGULATORY; TACROLIMUS;

EID: 77749324907     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22003     Document Type: Article

References (46)

1. Smith DM, Agura E, Netto G, Collins R, Levy M, Goldstein R, et al. Liver transplant-associated graft-versushost disease. Transplantation 2003;75:118-126.
2. Schrager JJ, Vnencak-Jones CL, Graber SE, Neff AT, Chari RS, Wright KJ, et al. Use of short tandem repeats for DNA fingerprinting to rapidly diagnose graft-versushost disease in solid organ transplant patients. Transplantation 2006;81:21-25.
3. Taylor AL, Gibbs P, Sudhindran S, Key T, Goodman RS, Morgan CH, et al. Monitoring systemic donor lymphocyte macrochimerism to aid the diagnosis of graft-versus-host disease after liver transplantation. Transplantation 2004;77:441-446.
4. Hahn AB, Baliga P. Rapid method for the analysis of peripheral chimerism in suspected graft-versus-host disease after liver transplantation. Liver Transpl 2000;6: 180-184.
5. Kuball J, Theobald M, Ferreira EA, Hess G, Burg J, Maccagno G, et al. Control of organ transplant-associated graft-versus-host disease by activated host lymphocyte infusions. Transplantation 2004;78:1774-1779.
6. Lehner F, Becker T, Sybrecht L, Luck R, Schwinzer R, Slateva K, et al. Successful outcome of acute graft-versus-host disease in a liver allograft recipient by withdrawal of immunosuppression. Transplantation 2002; 73:307-310.
7. Soejima Y, Shimada M, Suehiro T, Hiroshige S, Gondo H, Takami A, et al. Graft-versus-host disease following living donor liver transplantation. Liver Transpl 2004;10: 460-464.
8. Sudhindran S, Taylor A, Delriviere L, Collins VP, Liu L, Taylor CJ, et al. Treatment of graft-versus-host disease after liver transplantation with basiliximab followed by bowel resection. Am J Transplant 2003;3:1024-1029.
9. Riñón M, Maruri N, Arrieta A, Fernández JR, Ortiz de Urbina J, García Masdevall MD. Selective immunosuppression with daclizumab in liver transplantation with graft-versus-host disease. Transplant Proc 2002;34: 109-110.
10. Starzl TE, Demetris AJ, Trucco M, Murase N, Ricordi C, Ildstad S, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 1993;17:1127-1152.
11. Xue F, Chen W, Wang XG, Liang L, Bai XL, Wang LY, et al. Establishment of an acute graft-versus-host disease model following liver transplantation in donordominant one-way major histocompatibility complex matching rats. Transplant Proc 2009;41:1914-1920.
12. Xue F, Chen W, Wang XG, Wang L, Xu G, Liang L, et al. Regulatory T cells contribute to the immunoregulatory effect on graft versus host reaction after liver transplantation in donor-dominant one-way MHC matching rats. Transpl Immunol 2009;20:232-237.
13. Kamada N, Calne RY. A surgical experience with five hundred thirty liver transplants in the rat. Surgery 1983;93:64-69.
14. Burdick JF, Vogelsang GB, Smith WJ, Farmer ER, Bias WB, Kaufmann SH, et al. Severe graft-versus-host disease in a liver-transplant recipient. N Engl J Med 1988; 318:689-691.
15. Kohler S, Pascher A, Junge G, Sauer IM, Nagy M, Schonemann C, et al. Graft versus host disease after liver transplantation - a single center experience and review of literature. Transpl Int 2008;21:441-451.
16. Taylor AL, Gibbs P, Bradley JA. Acute graft versus host disease following liver transplantation: the enemy within. Am J Transplant 2004;4:466-474.
17. Shevach EM. Regulatory T cells in autoimmunity. Annu Rev Immunol 2000;18:423-449.
18. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000;12:431-440.
19. Field EH, Matesic D, Rigby S, Febr T, Rouse T, Gao Q. CD4+CD25+ regulatory cells in acquired MHC tolerance. Immunol Rev 2001;182:99-112.
20. Waldmann H, Chen TC, Graca L, Adams E, Daley S, Cobbold S, et al. Regulatory T cells in transplantation. Semin Immunol 2006;18:111-119.
21. Edinger M, Hoffman P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graftversus-host disease after bone marrow transplantation. Nat Med 2003;9:1144-1150.
22. Nguyen VH, Shashidhar S, Chang DS, Ho L, Kambham N, Bachmann M, et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood 2008;111:945-953.
23. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002;196:389-399.
24. Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL, et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versusleukemia. J Clin Invest 2003;112:1688-1696.
25. Zhao D, Zhang C, Yi T, Lin CL, Todorov I, Kandeel F, et al. In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood 2008;112:2129-2138.
26. Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004;16:1643-1656.
27. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007;7:1722-1732.
28. Baan C, van der Mast BJ, Klepper M, Mol WM, Peeters AM, Korevaar SS, et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005;80:110-117.
29. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+Foxp3+ regulatory T cells. Blood 2005;105:4743-4748.
30. Valmori D, Tosello V, Souleimanian NE, Godefroy E, Scotto L, Wang Y, et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+T cells. J Immunol 2006;177:944-949.
31. Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001;72:1924-1929.
32. Pidala J, Kim J, Anasetti C. Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009;15:881-885.
33. Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 26:5767-5774.
34. Alyea EP, Li S, Kim HT, Cutler C, Ho V, Soiffer RJ. Sirolimus, tacrolimus, and low-dose methotrexate as graftversus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2008;14:920-926.
35. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198: 1875-1886.
36. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004;172:5149-5153.
37. Liu Y, Zhang P, Li J, Kulkarni AB, Perruche S, Chen W. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol 2008;9:632-640.
38. Furtado G, de Lafaille MAC, Kutchukhidze N, Lafaille JJ. Interleukin-2 signaling is required for CD4+ regulatory T-cell function. J Exp Med 2002;196:851-857.
39. Thornton A, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004;172:6519-6523.
40. D'Cruz LM, Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005;6: 1152-1159.
41. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A functional role for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005;6:1142-1151.
42. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+)CD25(+)CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005;201:723-735.
43. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006;126: 375-387.
44. Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Burakoff SJ, Crabtree G, et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by alternative complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci USA 1990;87:9231-9235.
45. Dumont FJ, Melino MR, Staruch MJ, Koprak SL, Fischer PA, Sigal NH. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990;144:1418-1424.
46. Dodge IL, Demirci G, Strom TB, Li XC. Rapamycin induces transforming growth factor-beta production by lymphocytes. Transplantation 2000;70:1104-1106.